Spectrum of metabolic myopathies

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 4, 2015, Pages 615-621

  Angelini, Corrado ^a  

^a IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

Carnitine; Enzyme replacement therapy; Glycogenosis; Lipid storage myopathy

Indexed keywords

AUTOPHAGY; CARNITINE DEFICIENCY; CARNITINE PALMITOYL TRANSFERASE II DEFICIENCY; ENZYME REPLACEMENT; GENETIC DISORDER; GLYCOGEN STORAGE DISEASE TYPE 2; GLYCOGEN STORAGE DISEASE TYPE 3; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; LIPID STORAGE; LIPIDOSIS; METABOLIC MYOPATHY; MULTIPLE ACYL COA DEHYDROGENASE DEFICIENCY; MYOPATHY; NEUTRAL LIPID STORAGE MYOPATHY; PRIORITY JOURNAL; REVIEW; RIBOFLAVIN RESPONSIVE MULTIPLE ACYL COA DEHYDROGENASE DEFICIENCY; ANIMAL; DEFICIENCY; ENZYMOLOGY; GENETICS; GLYCOGEN STORAGE DISEASE; LIPID METABOLISM, INBORN ERRORS; MUSCULAR DISEASES; PATHOLOGY;

ELECTRON TRANSFERRING FLAVOPROTEIN; ELECTRON-TRANSFERRING-FLAVOPROTEIN DEHYDROGENASE; IRON SULFUR PROTEIN; OXIDOREDUCTASE;

ANIMALS; ELECTRON-TRANSFERRING FLAVOPROTEINS; ENZYME REPLACEMENT THERAPY; GLYCOGEN STORAGE DISEASE; HUMANS; IRON-SULFUR PROTEINS; LIPID METABOLISM, INBORN ERRORS; MUSCULAR DISEASES; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS;

EID: 84922335056     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.06.031     Document Type: Review

References (55)

1. Angelini C., Engel A.G. Comparative study of acid maltase deficiency. Biochemical differences between infantile, childhood, and adult types. Arch. Neurol. 1972, 26(4):344-349.
2. Hirschhorn R., Reuser A.J. Glycogen storage disease type II: acid alpha glucosidase (acid maltase) deficiency. The Metabolic and Molecular Bases of Inherited Disease 2001, 3389-3420. McGraw-Hill, New York. 8th edition. B.A. Scriver, W. Sly, D. Valle (Eds.).
3. Laforêt P., Nicolino M., Eymard P.B., Puech J.P., Caillaud C., Poenaru L., Fardeau M. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 2000, 55(8):1122-1128.
4. Herzog A., Hartung R., Reuser A.J., Hermanns P., Runz H., Karabul N., Gökce S., Pohlenz J., Kampmann C., Lampe C., Beck M., Mengel E. A cross-sectional single-centre study on Pompe disease in 42 German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet. J. Rare Dis. 2012, 7(1):35.
5. Kishnani P.S., Hwu W.L., Mandel H., Nicolino M., Yong F., Corzo D., Infantile-Onset Pompe Disease Natural History Study Group A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J. Pediatr. 2006, 148:671-676.
6. Hagemans M.L., Hop W.J., Van Doorn P.A., Reuser A.J., Van der Ploeg A.T. Course of disability and respiratory function in untreated late onset Pompe disease. Neurology 2006, 66(4):581-583.
7. Angelini C., Semplicini C., Ravaglia S., Bembi B., Servidei S., Pegoraro E., Moggio M., Filosto M., Sette E., Crescimanno G., Tonin P., Parini R., Morandi L., Marrosu G., Greco G., Musumeci O., Di Iorio G., Siciliano G., Donati M.A., Carubbi F., Ermani M., Mongini T., Toscano A., Italian G.S.D.I. Group. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4years. J. Neurol. 2012, 259(5):952-958.
8. Schüller A., Wenninger S., Strigl-Pill N., Schoser B. Toward deconstructing the phenotype of late-onset Pompe disease. Am. J. Med. Genet. C: Semin. Med. Genet. 2012, 160(1):80-88.
9. Hagemans M.L.C., Janssens A.C.J.W., Winkel L.P.F., Sieradzan K.A., Reuser A.J., Van Doorn P.A., Van der Ploeg A.T. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 2004, 63:1688-1692.
10. Gungor D., de Vries J.M., Hop W.C., Reuser A.J., van Doorn P.A., van der Ploeg A.T., Hagemans M.L. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J. Rare Dis. 2011, 6:34.
11. Tsuburaya R.S., Monma K., Oya Y., Nakayama T., Fukuda T., Sugie H., Hayashi Y.K., Nonaka I., Nishino I. Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology. Neuromuscul. Disord. 2012, 22:389-393.
12. Fukuda T., Ahearn M., Roberts A., Mattaliano R.J., Zaal K., Ralston E., Plotz P.H., Raben N. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol. Ther. 2006, 14(6):831-839.
13. Raben N., Takikita S., Pittis M.G., Bembi B., Marie S.K., Roberts A., Page L., Kishnani P.S., Schoser B.G., Chien Y.H., Ralston E., Nagaraju K., Plotz P.H. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand. Autophagy 2007, 3(6):546-552.
14. Nascimbeni A.C., Fanin M., Masiero E., Angelini C., Sandri M. The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII). Cell Death Differ. 2012, 19(10):1698-1708.
15. Kishnani P.S., Nicolino M., Voit T., Rogers R.C., Tsai A.C., Waterson J., Herman G.E., Amalfitano A., Thurberg B.L., Richards S., Davison M., Corzo D., Chen Y.T. Chinese hamster ovary cell-derived recombinant human acid a-glucosidase in infantile-onset Pompe disease. J. Pediatr. 2006, 149:89-97.
16. van der Ploeg A.T. Where do we stand in enzyme replacement therapy in Pompe's disease?. Neuromuscul. Disord. 2010, 20(12):773-774.
17. Ebbink B.J., Aarsen F.K., van Gelder C.M. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology 2012, 78(19):1512-1518.
18. Prater S.N., Banugaria S.G., DeArmey S.M., Botha E.G., Stege E.M., Case L.E., Jones H.N., Phornphutkul C., Wang R.Y., Young S.P., Kishnani P.S. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet. Med. 2012, 14(9):800-810.
19. van der Ploeg A.T., Clemens P.R., Corzo D., Escolar D.M., Florence J., Groeneveld G.J., Herson S., Kishnani P.S., Laforet P., Lake S.L., Lange D.J., Leshner R.T., Mayhew J.E., Morgan C., Nozaki K., Park D.J., Pestronk A., Rosenbloom B., Skrinar A., van Capelle C.I., van der Beek N.A., Wasserstein M., Zivkovic S.A. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N. Engl. J. Med. 2010, 362(15):1396-1406.
20. Regnery C., Kornblum C., Hanisch F., Vielhaber S., Strigl-Pill N., Grunert B., Müller-Felber W., Glocker F.X., Spranger M., Deschauer M., Mengel E., Schoser B. 36months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J. Inherit. Metab. Dis. 2012, 35(5):837-845.
21. Angelini C., Semplicini C., Ravaglia S., Moggio M., Comi G.P., Musumeci O., Pegoraro E., Tonin P., Filosto M., Servidei S., Morandi L., Crescimanno G., Marrosu G., Siciliano G., Mongini T., Toscano A., Italian Group on GSDII New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy. Muscle Nerve 2012, 45(6):831-834.
22. Carlier R.Y., Laforet P., Wary C., Mompoint D., Laloui K., Pellegrini N., Annane D., Carlier P.G., Orlikowski D. Whole body muscle MRI in 20 patients suffering from late onset Pompe disease: involvement patterns. Neuromuscul. Disord. 2011, 21:791-799.
23. Toscano A., Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J. Neurol. 2013, 260(4):951-959.
24. Cupler E.J., Berger K.I., Leshner R.T., Wolfe G.I., Han J.J., Barohn R.J., Kissel J.T., AANEM Consensus Committee on Late-onset Pompe Disease Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012, 45:319-333.
25. Kishnani P.S., Beckemeyer A.A., Mendelsohn N.J. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. Am. J. Med. Genet. C: Semin. Med. Genet. 2012, 160:1-7.
26. Orlikowski D., Pellegrini N., Prigent H., Laforêt P., Carlier R., Carlier P., Eymard B., Lofaso F., Annane D. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuromuscul. Disord. 2011, 21:477-482.
27. Okubo M., Spengos K., Manta P., Fateen E. Phenotypical variability in glycogen storage disease type III with a recurrent AGL mutation c.750-753delAGAC. Muscle Nerve 2011, 43(3):451.
28. Dagli A., Sentner C.P., Weinstein D.A. Glycogen storage disease type III. GeneReviews™ 2010, [Internet], University of Washington, Seattle, Seattle (WA), (Available from: http://www.ncbi.nlm.nih.gov/books/NBK26372/). R.A. Pagon, T.D. Bird, C.R. Dolan (Eds.).
29. Kishnani P.S., Austin S.L., Arn P., Bali D.S., Boney A., Case L.E., Chung W.K., Desai D.M., El-Gharbawy A., Haller R., Smit G.P., Smith A.D., Hobson-Webb L.D., Wechsler S.B., Weinstein D.A., Watson M.S. Glycogen storage disease type III diagnosis and management guidelines. Genet. Med. 2010, 12:446-463.
30. Valayannopoulos V., Bajolle F., Arnoux J.B., Dubois S., Sannier N., Baussan C., Petit F., Labrune P., Rabier D., Ottolenghi C., Vassault A., Broissand C., Bonnet D., de Lonlay P. Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D, L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr. Res. 2011, 70(6):638-641.
31. Quinlivan R., Buckley J., James M., Twist A., Ball S., Duno M., Vissing J., Bruno C., Cassandrini D., Roberts M., Winer J., Rose M., Sewry C. McArdle disease: a clinical review. J. Neurol. Neurosurg. Psychiatry 2010, 81(11):1182-1188.
32. Lucia A., Ruiz J.R., Santalla A., Nogales-Gadea G., Rubio J.C., García-Consuegra I., Cabello A., Pérez M., Teijeira S., Vieitez I., Navarro C., Arenas J., Martin M.A., Andreu A.L. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J. Neurol. Neurosurg. Psychiatry 2012, 83(3):322-328.
33. Haller R.G., Dempsey W.B., Feit H., Cook J.D., Knochel J.P. Low muscle levels of pyridoxine in McArdle's syndrome. Am. J. Med. 1983, 74:217-220.
34. Sato S., Ohi T., Nishino I., Sugie H. Confirmation of the efficacy of vitamin B6 supplementation for McArdle disease by follow-up muscle biopsy. Muscle Nerve 2012, 45(3):436-440.
35. Quinlivan R., Martinuzzi A., Schoser B. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). Cochrane Database Syst. Rev. 2010, 8(12):CD003458.
36. Quinlivan R., Vissing J., Hilton-Jones D., Buckley J. Physical training for McArdle disease. Cochrane Database Syst. Rev. 2011, 7(12):CD007931.
37. Andersen S.T., Haller R.G., Vissing J. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch. Neurol. 2008, 65(6):786-789.
38. Andersen S.T., Vissing J. Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity. J. Neurol. Neurosurg. Psychiatry 2008, 79(12):1359-1363. (Erratum in: J Neurol Neurosurg Psychiatry 2010; 81(12): 1414).
39. Lucia A., Quinlivan R., Wakelin A., Martín M.A., Andreu A.L. The 'McArdle paradox': exercise is a good advice for the exercise intolerant. Br. J. Sports Med. 2013, 47(12):728-729.
40. Martinuzzi A., Sartori E., Fanin M., Nascimbeni A., Valente L., Angelini C., Siciliano G., Mongini T., Tonin P., Tomelleri G., Toscano A., Merlini L., Bindoff L.A., Bertelli S. Phenotype modulators in myophosphorylase deficiency. Ann. Neurol. 2003, 53:497-502.
41. Martinuzzi A., Liava A., Trevisi E., Frare M., Tonon C., Malucelli E., Manners D., Kemp G.J., Testa C., Barbiroli B., Lodi R. Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. Muscle Nerve 2008, 37(3):350-357.
42. Engel A.G., Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 1973, 179(4076):899-902.
43. Karpati G., Carpenter S., Engel A.G., Watters G., Allen J., Rothman S., Klassen G., Mamer O.A. The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and pathophysiologic features. Neurology 1975, 25(1):16-24.
44. Chapoy P.R., Angelini C., Brown W.J., Stiff J.E., Shug A., Cederbaum S.D. Systemic carnitine deficiency - a treatable inherited lipid-storage disease presenting as Reye's syndrome. N. Engl. J. Med. 1980, 303:1389-1394.
45. Fischer J., Lefevre C., Morava E., Mussini J.M., Laforet P., Negre-Salvayre A., Lathrop M., Salvayre R. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat. Genet. 2007, 39:28-30.
46. Campagna F., Nanni L., Quagliarini F., Pennisi E., Michailidis C., Pierelli F., Bruno C., Casali C., DiMauro S., Arca M. Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy. Biochem. Biophys. Res. Commun. 2008, 377:843-846.
47. Wang Z.Q., Chen X.J., Murong S.X., Wang N., Wu Z.Y. Molecular analysis of 51 unrelated pedigrees with late-onset multiple acyl-CoAdehydrogenation deficiency (MADD) in southern China confirmed the most common ETFDH mutation and high carrier frequency of c.250G>A. J. Mol. Med. 2011, 89(6):569-576.
48. Liang W.C., Nishino I. Lipid storage myopathy. Curr. Neurol. Neurosci. Rep. 2011, 11:97-103.
49. Cornelius N., Frerman F.E., Corydon T.J., Palmfeldt J., Bross P., Gregersen N., Olsen R.K. Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency. Hum. Mol. Genet. 2012, 21(15):3435-3448.
50. Liang W.C., Nishino I. State of the art in muscle lipid diseases. Acta Myol. 2010, 29(2):351-356.
51. Fanin M., Anichini A., Cassandrini D., Fiorillo C., Scapolan S., Minetti C., Cassanello M., Donati M., Siciliano G., D'Amico A., Lilliu F., Bruno C., Angelini C. Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency. Clin. Genet. 2012, 82(3):232-239.
52. Ørngreen M.C., Ejstrup R., Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology 2003, 61(4):559-561.
53. Ørngreen M.C., Olsen D.B., Vissing J. Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. Neurology 2002, 59(7):1046-1051.
54. Bonnefont J.P., Bastin J., Behin A., Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N. Engl. J. Med. 2009, 360(8):838-840.
55. Bonnefont J.P., Bastin J., Laforêt P., Aubey F., Mogenet A., Romano S., Ricquier D., Gobin-Limballe S., Vassault A., Behin A., Eymard B., Bresson J.L., Djouadi F. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin. Pharmacol. Ther. 2010, 88(1):101-108.